149 related articles for article (PubMed ID: 33720853)
1. Plasma Lipopolysaccharide-Binding Protein Reflects Risk and Progression of Parkinson's Disease.
Chen SJ; Chi YC; Ho CH; Yang WS; Lin CH
J Parkinsons Dis; 2021; 11(3):1129-1139. PubMed ID: 33720853
[TBL] [Abstract][Full Text] [Related]
2. Plasma pS129-α-Synuclein Is a Surrogate Biofluid Marker of Motor Severity and Progression in Parkinson's Disease.
Lin CH; Liu HC; Yang SY; Yang KC; Wu CC; Chiu MJ
J Clin Med; 2019 Oct; 8(10):. PubMed ID: 31623323
[TBL] [Abstract][Full Text] [Related]
3. Alteration of Gut Microbial Metabolites in the Systemic Circulation of Patients with Parkinson's Disease.
Chen SJ; Chen CC; Liao HY; Wu YW; Liou JM; Wu MS; Kuo CH; Lin CH
J Parkinsons Dis; 2022; 12(4):1219-1230. PubMed ID: 35342048
[TBL] [Abstract][Full Text] [Related]
4. Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD).
Williams-Gray CH; Wijeyekoon R; Yarnall AJ; Lawson RA; Breen DP; Evans JR; Cummins GA; Duncan GW; Khoo TK; Burn DJ; Barker RA;
Mov Disord; 2016 Jul; 31(7):995-1003. PubMed ID: 26999434
[TBL] [Abstract][Full Text] [Related]
5. Blood NfL: A biomarker for disease severity and progression in Parkinson disease.
Lin CH; Li CH; Yang KC; Lin FJ; Wu CC; Chieh JJ; Chiu MJ
Neurology; 2019 Sep; 93(11):e1104-e1111. PubMed ID: 31420461
[TBL] [Abstract][Full Text] [Related]
6. Peripheral inflammatory cytokines and motor symptoms in persons with Parkinson's disease.
Diaz K; Kohut ML; Russell DW; Stegemöller EL
Brain Behav Immun Health; 2022 May; 21():100442. PubMed ID: 35308082
[TBL] [Abstract][Full Text] [Related]
7. Lipopolysaccharide-binding protein and future Parkinson's disease risk: a European prospective cohort.
Zhao Y; Walker DI; Lill CM; Bloem BR; Darweesh SKL; Pinto-Pacheco B; McNeil B; Miller GW; Heath AK; Frissen M; Petrova D; Sánchez MJ; Chirlaque MD; Guevara M; Zibetti M; Panico S; Middleton L; Katzke V; Kaaks R; Riboli E; Masala G; Sieri S; Zamora-Ros R; Amiano P; Jenab M; Peters S; Vermeulen R
J Neuroinflammation; 2023 Jul; 20(1):170. PubMed ID: 37480114
[TBL] [Abstract][Full Text] [Related]
8. Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort.
Regnault A; Boroojerdi B; Meunier J; Bani M; Morel T; Cano S
J Neurol; 2019 Aug; 266(8):1927-1936. PubMed ID: 31073716
[TBL] [Abstract][Full Text] [Related]
9. Cytokine profiles of plasma extracellular vesicles as progression biomarkers in Parkinson's disease.
Chan L; Chung CC; Yu RC; Hong CT
Aging (Albany NY); 2023 Mar; 15(5):1603-1614. PubMed ID: 36897204
[TBL] [Abstract][Full Text] [Related]
10. Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa).
Mollenhauer B; Zimmermann J; Sixel-Döring F; Focke NK; Wicke T; Ebentheuer J; Schaumburg M; Lang E; Friede T; Trenkwalder C;
Mov Disord; 2019 Jan; 34(1):67-77. PubMed ID: 30468694
[TBL] [Abstract][Full Text] [Related]
11. Cytokine Profile in Plasma Extracellular Vesicles of Parkinson's Disease and the Association with Cognitive Function.
Chan L; Chung CC; Chen JH; Yu RC; Hong CT
Cells; 2021 Mar; 10(3):. PubMed ID: 33803292
[TBL] [Abstract][Full Text] [Related]
12. Prediction of depression and anxiety via patient-assessed tremor severity, not physician-reported motor symptom severity, in patients with Parkinson's disease or essential tremor who have undergone deep brain stimulation.
Achey RL; Yamamoto E; Sexton D; Hammer C; Lee BS; Butler RS; Thompson NR; Nagel SJ; Machado AG; Lobel DA
J Neurosurg; 2018 Dec; 129(6):1562-1571. PubMed ID: 29473781
[TBL] [Abstract][Full Text] [Related]
13. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.
Latourelle JC; Beste MT; Hadzi TC; Miller RE; Oppenheim JN; Valko MP; Wuest DM; Church BW; Khalil IG; Hayete B; Venuto CS
Lancet Neurol; 2017 Nov; 16(11):908-916. PubMed ID: 28958801
[TBL] [Abstract][Full Text] [Related]
14. Altered gut microbiota and inflammatory cytokine responses in patients with Parkinson's disease.
Lin CH; Chen CC; Chiang HL; Liou JM; Chang CM; Lu TP; Chuang EY; Tai YC; Cheng C; Lin HY; Wu MS
J Neuroinflammation; 2019 Jun; 16(1):129. PubMed ID: 31248424
[TBL] [Abstract][Full Text] [Related]
15. Predicting Progression in Parkinson's Disease Using Baseline and 1-Year Change Measures.
Chahine LM; Siderowf A; Barnes J; Seedorff N; Caspell-Garcia C; Simuni T; Coffey CS; Galasko D; Mollenhauer B; Arnedo V; Daegele N; Frasier M; Tanner C; Kieburtz K; Marek K;
J Parkinsons Dis; 2019; 9(4):665-679. PubMed ID: 31450510
[TBL] [Abstract][Full Text] [Related]
16. Assessing the relationship between non-motor symptoms and health-related quality of life in Parkinson's disease: a retrospective observational cohort study.
Ueno T; Kon T; Haga R; Nishijima H; Arai A; Tomiyama M
Neurol Sci; 2020 Oct; 41(10):2867-2873. PubMed ID: 32328832
[TBL] [Abstract][Full Text] [Related]
17. Plasma α-synuclein predicts cognitive decline in Parkinson's disease.
Lin CH; Yang SY; Horng HE; Yang CC; Chieh JJ; Chen HH; Liu BH; Chiu MJ
J Neurol Neurosurg Psychiatry; 2017 Oct; 88(10):818-824. PubMed ID: 28550072
[TBL] [Abstract][Full Text] [Related]
18. Association of Polygenic Risk Score With Cognitive Decline and Motor Progression in Parkinson Disease.
Paul KC; Schulz J; Bronstein JM; Lill CM; Ritz BR
JAMA Neurol; 2018 Mar; 75(3):360-366. PubMed ID: 29340614
[TBL] [Abstract][Full Text] [Related]
19. COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global--clinical evaluations, serum biomarkers, genetic studies and neuroimaging--prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression.
Santos-García D; Mir P; Cubo E; Vela L; Rodríguez-Oroz MC; Martí MJ; Arbelo JM; Infante J; Kulisevsky J; Martínez-Martín P;
BMC Neurol; 2016 Feb; 16():26. PubMed ID: 26911448
[TBL] [Abstract][Full Text] [Related]
20. Systemic activation of NLRP3 inflammasome and plasma α-synuclein levels are correlated with motor severity and progression in Parkinson's disease.
Fan Z; Pan YT; Zhang ZY; Yang H; Yu SY; Zheng Y; Ma JH; Wang XM
J Neuroinflammation; 2020 Jan; 17(1):11. PubMed ID: 31915018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
